Roche Diagnostics promotes Dan Zabrowski

To head of Roche Applied Science

Dan Zabrowski has succeeded Paul Brown as head of Roche Applied Science in the Diagnostics Division, located in Penzberg, Germany.

Zabrowski was recently global head of Roche Partnering and a member of the Roche corporate executive committee and Chugai board. He joined Roche in 1994 through the acquisition of Syntex. While at Roche he has held a number of management positions in regulatory affairs and development.

You may also like

Research & Development
Lab standardisation: working smarter to improve patient outcomes

Lab standardisation: working smarter to improve patient outcomes

We’re living in a pivotal time for healthcare, reports Benjamin Lilienfeld, LifeCycle Leader at Roche Diagnostics Solutions. An advanced understanding of diseases, innovative techniques and treatments, a dizzying array of new technologies and a growing population of empowered and knowledgeable patients and caregivers have, together, made healthcare systems increasingly complex
Ingredients
Horizon Discovery enters into agreement with Roche Diagnostics

Horizon Discovery enters into agreement with Roche Diagnostics

Horizon Discovery Group, a specialist in gene editing and gene modulation technologies, announced it has entered into an agreement with Roche Diagnostics to assist in the development of immunohistochemistry (IHC) assays
Distribution
Merck expands distribution agreement with Roche

Merck expands distribution agreement with Roche

Merck to be the exclusive supplier of novel enzymes for polymerase chain reaction (PCR) and quantitative real-time PCR, for all countries except the US, Brazil and Japan
Manufacturing

Roche to invest CHF450m in new diagnostic manufacturing facility in China

To address Asia Pacific’s growing demand for diagnostic tests
You need to be a subscriber to read this article.
Click here to find out more.
Regulatory
Reimbursment issues hinder future development of personal therapies

Reimbursment issues hinder future development of personal therapies

The development of more targeted therapies is moving apace, but are the payers prepared for it? Dr Sarah Houlton looks at the progress of personalised medicines
Regulatory

FDA approves MycoTOOL mycoplasma PCR test

Test reduces time for detection from one month to one day
Manufacturing
Roche announces launch of CE certified MagNA Pure 96 System

Roche announces launch of CE certified MagNA Pure 96 System

For reliable and automated nucleic acid extraction
Subscribe now